Answers are grounded in this paper and cite their sources.
Short-read genome sequencing (GS) has become a powerful first-tier test for children with suspected neurogenetic disease, yet its diagnostic yield plateaus near 40%, leaving most families without an answer. The undiagnosed remainder is not one problem but a collection of mechanistically distinct lesions, including cryptic splice-altering and regulatory variants, repeat expansions, and complex structural rearrangements, frequently missed or uninterpretable on short-read GS. Layering GS with RNA sequencing (RNA-seq) and long-read sequencing (LRS) resolves many of these cases. The central challenge is no longer whether multi-omic methods add diagnostic power, but how to deliver them as a routine, standardized, and equitable clinical service rather than an ad hoc research effort. Here we describe an integrated multi-omic diagnostic pathway built across the University of Utah and Primary Children’s Hospital for a largely rural, underserved catchment area. The pathway couples uniform GS delivery (the NeoSeq, TeleGenetics, and Gene Kids programs) with AI-assisted patient identification (Mendelian Phenotype Search Engine, MPSE) and a registry of non-diagnostic genomes subjected to multi-omic reanalysis (Neo/ReSeq). We focus on the design questions that determine whether multi-omics succeeds at scale: which modality to deploy for which patient, how source-tissue selection governs RNA-seq interpretability, how to allocate finite RNA-seq and LRS capacity, and how to embed equity so its power does not accrue only to the already-advantaged. We emphasize the architecture rather than cohort results, which are reported separately, and argue that an integrated, lifelong multi-omic strategy is the realistic path to closing the diagnostic gap in pediatric neurogenetic disease.
No takes yet. Share an insight, caveat, or question.
Shayota et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: